SUSMEDInc Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Taro Ueno

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	41.4%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Taro Ueno (44 yo)

no data

Mandato

Mr. Taro Ueno is CEO, President and Chairman at SUSMED,Inc.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Taro Ueno	Chairman	no data	Nessun dato	41.38% ¥ 4.2b
Tomomitsu Motohashi	CTO & Director	5.2yrs	Nessun dato	1.01% ¥ 101.5m
Takayuki Kohara	Director of Administration & Director	3.5yrs	Nessun dato	0.033% ¥ 3.4m
Kenta Nagao	Audit & Supervisory Board Member	4.2yrs	Nessun dato	0.058% ¥ 5.9m
Makiko Yamamoto	Audit & Supervisory Board Member	3.2yrs	Nessun dato	Nessun dato
Kuniaki Kaga	Independent Outside Director	3.8yrs	Nessun dato	0.0030% ¥ 299.2k
Yoshiko Akishima	Chairman of Audit & Supervisory Board	5.2yrs	Nessun dato	0.067% ¥ 6.7m

4.0yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4263 sono considerati esperti (durata media dell'incarico 4 anni).

SUSMEDInc Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

SUSMED,Inc., Annual General Meeting, Sep 27, 2024

SUSMED,Inc., Annual General Meeting, Sep 29, 2023

Less than half of directors are independent

SUSMED,Inc., Annual General Meeting, Sep 29, 2022

No independent directors

Recent updates

First quarter 2025 earnings released: JP¥9.73 loss per share (vs JP¥8.78 loss in 1Q 2024)

Full year 2024 earnings released: JP¥21.39 loss per share (vs JP¥3.05 loss in FY 2023)

SUSMED,Inc. to Report Q1, 2025 Results on Nov 08, 2024

SUSMED,Inc., Annual General Meeting, Sep 27, 2024

New minor risk - Share price stability

Now 54% undervalued

Forecast to breakeven in 2027

Now 23% undervalued

SUSMED,Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024

Third quarter 2024 earnings released: JP¥7.60 loss per share (vs JP¥16.96 profit in 3Q 2023)

SUSMED,Inc. to Report Q3, 2024 Results on May 10, 2024

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: JP¥3.30 (vs JP¥5.99 loss in 2Q 2023)

Now 21% overvalued

New minor risk - Market cap size

New major risk - Share price stability

SUSMED,Inc. to Report Q2, 2024 Results on Feb 14, 2024

New major risk - Share price stability

First quarter 2024 earnings released: JP¥8.78 loss per share (vs JP¥5.66 loss in 1Q 2023)

SUSMED,Inc. to Report Q1, 2024 Results on Nov 10, 2023

New major risk - Share price stability

Forecast to breakeven in 2025

SUSMED,Inc., Annual General Meeting, Sep 29, 2023

SUSMED,Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: JP¥5.99 loss per share (vs JP¥5.40 loss in 2Q 2022)

SUSMED,Inc. to Report Q2, 2023 Results on Feb 10, 2023

Less than half of directors are independent

Full year 2022 earnings released: JP¥15.87 loss per share (vs JP¥21.65 loss in FY 2021)

SUSMED,Inc. to Report Q1, 2023 Results on Nov 11, 2022

SUSMED,Inc., Annual General Meeting, Sep 29, 2022

Full year 2022 earnings released: JP¥15.87 loss per share (vs JP¥21.65 loss in FY 2021)

SUSMED,Inc. to Report Q4, 2022 Results on Aug 12, 2022

No independent directors

SUSMED,Inc. to Report Q3, 2022 Results on May 12, 2022

SUSMED,Inc. has completed an IPO in the amount of ¥3.65613 billion.

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media